Abstract
To report the impact of an inpatient anticoagulation stewardship program at a community hospital to promote optimal anticoagulant use. The anticoagulation team (ACT) stewardship program consists of two clinical pharmacists and hematologists to provide oversight of anticoagulants, high cost reversal agents including prothrombin complex concentrate (PCC, Kcentra™), and heparin-induced thrombocytopenia (HIT) management. Intervention data and number of charts reviewed were collected. Average cost avoidance data was applied to ACT interventions to estimate cost savings. The PCC analysis was conducted via retrospective chart review during the pre-intervention period. Prospective monitoring continued in the post-intervention period to determine the percentage of PCC use within the institution’s guidelines or approved by ACT or hematology. A total of 19,445 patient charts were reviewed, and 1930 (10%) contained stewardship opportunity. Of the interventions, 71% were provided to the medical service and 22% to surgical services with acceptance rates of 91 and 83%, respectively. Intervention cost-avoidance calculated to be $694,217. Regarding HIT interventions, 52% of interventions involved pharmacokinetic/pharmacodynamics optimization in 18 patients with suspected or confirmed HIT. Regarding PCC use, 55.8% of PCC orders were considered inappropriate in the pre-invention period versus 2.6% post-intervention. Appropriate PCC doses per month post-intervention were consistent with pre-intervention doses (7.67 vs. 6.73, respectively). The projected annual PCC cost savings is $385,473. The overall estimated financial impact of ACT is $799,690 saved. Implementation of an anticoagulation stewardship program reduced costs and improved clinical outcomes. It is also expected that anticoagulant optimization and provider education improved overall safety.
Similar content being viewed by others
References
Barnes GD, Lucas E, Alexander GC, Goldberger ZD (2015) National trends in ambulatory oral anticoagulant use. Am J Med 128:1300–1305
Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE, Garcia DA (2013) Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum. Ann Pharmacother 47:714–724
Institute for Safe Medica tion Practices (ISMP). Quarter Watch: Monitoring FDA MedWatch Reports, September 2015. https://www.ismp.org/quarterwatch/pdfs/2014Q4.pdf. Accessed 31 May 2016
American Society of Health-System Pharmacists (ASHP). A Hospital Pharmacist’s Guide to Antimicrobial Stewardship Programs. http://www.ashpadvantage.com/docs/stewardship-white-paper.pdf. Accessed 31 May 2016
Barlam TF, Cosgrove SE, Abbo LM et al (2016) Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 62:e51–e77
Przybylski KG, Rybak MJ, Martin PR et al (1997) A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy 17:271–276
U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. National Action Plan for Adverse Drug Event Prevention. Washington, DC, 2014. http://health.gov/hcq/pdfs/ade-action-plan-508c.pdf. Accessed 31 May 2016
Padron M, Miyares MA (2015) Development of an anticoagulation stewardship program at a large tertiary care academic institution. J Pharm Pract 28:93–98
Reardon DP, Atay JK, Ashley SW, Churchill WW, Berliner N, Connors JM (2015) J Thromb Thrombolysis 40:379–382
Trueg AO, Lowe C, Kiel PJ (2015) Clinical outcomes of a pharmacy-led blood factor stewardship program. Am J Ther 0:1–5
Amerine LB, Chen S, Daniels R, Key N, Eckel SF, Savage SW (2015) Impact of an innovative blood factor stewardship program on drug expense and patient care. Am J Health-Syst Pharm 72:1579–1584
Ritchie BM, Sylvester KW, Reardon DP et al (2016) Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program. J Thromb Thrombolysis 42:616–622
Board of Pharmacy Specialties for Pharmacotherapy. http://www.bpsweb.org/bps-specialties/pharmacotherapy/. Accessed 20 Sept 2016
Anticoagulation Forum, Anticoagulation Boot Camp. http://acforumbootcamp.org/2016-ALB/index.php. Accessed 20 Sept 2016
American Society of Health-System Pharmacists Foundation Advanced Antithrombotic Management Traineeship. http://www.ashpfoundation.org/MainMenuCategories/Traineeships/PharmacotherapyTraineeship. Accessed 20 Sept 2016
National Certification Board for Anticoagulation Providers. http://www.ncbap.org/aboutcacpexam.aspx. Accessed 20 Sept 2016
Lee AJ, Boro MS, Knapp KK, Meier JL, Korman NE (2002) Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health-Syst Pharm 59:2070–2077
Warkentin TE, Linkins LA (2010) Non-necrotizing Heparin-induced Skin Lesions and the 4T’s score. J Thromb Haemost 8:1483–1485
Ghadimi K, Dombrowski KE, Levy JH, Welsby IJ (2016) Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Expert Rev Hematol 9:115–122
Dellit TH, Owens RC, McGown JE Jr et al (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis 44:159–177
Acknowledgements
The authors would like to thank Dr. Bob Reiss, Clinical Pharmacy Coordinator, and Dr. Robert Mayo, Chief Medical Officer, for their vision and leadership in making ACT a reality.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Peter A. Kouides and Maura K. Wychowski have received honoraria for participation in a scientific advisory board for Portola Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Wychowski, M.K., Ruscio, C.I., Kouides, P.A. et al. The scope and value of an anticoagulation stewardship program at a community teaching hospital. J Thromb Thrombolysis 43, 380–386 (2017). https://doi.org/10.1007/s11239-016-1455-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-016-1455-z